24.05.2026, 1323 Zeichen

Marinomed: Marinomed Biotech AG announced the signing of a term sheet with Phargentis SA. The term sheet contains the worldwide licensing of the proprietary Marinosolv® technology platform for the development of a high-performance formulation with a combination of different active pharmaceutical ingredients specifically designated for inhalation. Under the terms of the agreement, Marinomed will provide specialized formulation services and technical expertise to develop a respiratory therapeutic utilizing the Marinosolv® platform. This technology is designed to significantly increase the solubility and bioavailability of hydrophobic compounds, enabling more effective delivery to the lungs and potentially reducing the required dosage for patients. The financial structure of the partnership includes immediate fee-for-service components for the initial development phases. Furthermore, Marinomed is eligible to receive milestone payments tied to specific technical and clinical achievements throughout the development lifecycle, spanning several years. Upon successful commercialization, the agreement also stipulates the payment of royalties on net sales of the resulting product.
Marinomed Biotech: weekly performance: -4.00%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (19/05/2026)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1162: Pfingstmontag bringt ATX und DAX grosse Aufschläge, AT&S kurz nach Rebalancing schon wieder Top-Gewicht

Bildnachweis

Aktien auf dem Radar:AT&S, FACC, Infineon, Vonovia SE, Merck Co..

---